Brian Wolpin, MD
Enriched profileProfessor of Medicine, Harvard Medical School; Director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute · Dana-Farber Cancer Institute
Brian Wolpin is Professor of Medicine, Harvard Medical School; Director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute at Dana-Farber Cancer Institute. OpenAlex indexes 1,250 publications with 30,999 citations (h-index 89); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Brian M. Wolpin, MD, is Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. The public record shows 1,250 publications with 30,999 citations (h-index 89), centered on Pancreatic Cancer. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 4 companies, 4 NIH-funded awards (2009–2026).
- Top research focus: Pancreatic Cancer
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 38 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Member
Scientific and Medical Advisory Board (SMAB), Pancreatic Cancer Action Network (PanCAN), effective July 1
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pancan.org ↗ - Chair
NCI Pancreatic Cancer Detection Consortium Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labs.dana-farber.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
Sponsor: Abramson Cancer Center at Penn Medicine
- Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
Sponsor: Mayo Clinic
- OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 27 Aug 2026
4 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Ipsen Biopharmaceuticals, IncProgram year20232 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Substance P/Neurokinin-1 Receptor Antagonist100%Aprepitant100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- Altered metabolism and machine learning for pancreatic cancer early detection
Dana-Farber Cancer Inst
FY2025$828,138U01CA210171
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2021
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/brian-wolpin-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Brian-M-Wolpin-38492873/publications/1
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗ - ResearchGate
researchgate.net/scientific-contributions/Brian-Wolpin-2138453463
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_dr-brian-wolpinjpg-activity-6240182235815772160-4P2W
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Other
wbur.org/onpoint/2026/07/08/pill-bringing-new-hope-to-pancreatic-cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →wbur.org ↗ - X / Twitter
x.com/DanaFarberNews/status/1732105052448317859
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- MPH
Harvard T.H. Chan School of Public Health
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →labs.dana-farber.org ↗ - Board Certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Director
Gastrointestinal Cancer Center, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Director
Hale Family Center for Pancreatic Cancer Research, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Chief
Division of Gastrointestinal Oncology, Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Awards & honors
honors on the public record- Top Doctor Award2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Robert T. and Judith B. Hale Chair in Pancreatic Cancer
Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Brigham and Women's Hospital
Boston, MA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗ - Member
NCCN Pancreatic Adenocarcinoma Guidelines Panel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →labs.dana-farber.org ↗ - Member
Alliance for Clinical Trials in Oncology, Gastrointestinal Cancer Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →labs.dana-farber.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →wbur.org ↗
- ASCO Post video: Brian M. Wolpin
MD, MPH and Eileen M. O'Reilly, MD, on Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute